John Overdeck’s Liminatus Pharma LIMN Stock Holding History

John Overdeck’s Portfolio LIMN Stock Details LIMN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-706	Closed	-$21.5K	–	5021
2025 Q4	$21.5K	Buy	+706	New	+$39.2K	﹤0.01%	3992

Other funds holding LIMN

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Personalized Indexing Management Oakland, California $12.2B AUM 47.93% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

TSS

Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

John Overdeck's LIMN Position: Q1 2026 in Review

John Overdeck sold out of Liminatus Pharma (LIMN) in Q1 2026, closing a stake of 706 shares — an estimated $21.5K sold.

John Overdeck first reported a position in LIMN in Q4 2025 and held it in 1 quarter. The position peaked at $21.5K in Q4 2025. 14 funds tracked by Wall St. Rank hold LIMN as of Q1 2026.

John Overdeck reported no remaining Liminatus Pharma position as of Q1 2026 after selling out during the quarter.
John Overdeck sold 706 Liminatus Pharma shares in Q1 2026, an estimated $21.5K.
John Overdeck first reported a position in Liminatus Pharma in Q4 2025 and held it in 1 quarter.
John Overdeck's Liminatus Pharma position peaked at $21.5K in Q4 2025.
14 funds tracked by Wall St. Rank held Liminatus Pharma as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.